HUTCHMED (China) Limited (HCM)
Automate Your Wheel Strategy on HCM
With Tiblio's Option Bot, you can configure your own wheel strategy including HCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HCM
- Rev/Share 0.5287
- Book/Share 0.6475
- PB 4.2072
- Debt/Equity 0.1182
- CurrentRatio 2.8323
- ROIC -0.0398
- MktCap 2337634150.0
- FreeCF/Share -0.0146
- PFCF -134.0694
- PE 84.7404
- Debt/Assets 0.0705
- DivYield 0
- ROE 0.0503
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HCM | HSBC Securities | Buy | Hold | -- | -- | May 13, 2025 |
News
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA.
Read More
HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestone
Published: April 22, 2025 by: Proactive Investors
Sentiment: Positive
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial of its cancer drug savolitinib in China. The study is testing the treatment in people with gastric or gastroesophageal junction cancer whose tumours show MET gene amplification - a relatively rare but aggressive subtype.
Read More
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification.
Read More
3 Internet Delivery Services Stocks in Focus Amid Industry Challenges
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Tariff war, inflationary pressure and still-high interest rates are major concerns for the Zacks Internet - Delivery Services industry. However, efforts to adopt consumer preferences and technological advancements are likely to help GDDY, QNST and ASUR navigate the headwinds.
Read More
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 13, 2025 (“AGM”).
Read More
US pharma restrictions won't affect Hutchmed operations, says CEO
Published: March 20, 2025 by: CNBC International TV
Sentiment: Positive
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external challenges.
Read More
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting —
Read More
HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
HUTCHMED (China) Limited (NASDAQ:HCM ) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO George Yuan - Head of Commercial Michael Shi - EVP, Head of R&D & Chief Medical Officer Conference Call Participants Clara Dong - Jefferies Alec Stranahan - Bank of America Julie Simmonds - Panmure Liberum Adam McCarter - Cavendish Chen Chen - UBS Cindy Chai - HSBC David Ng Welcome, everyone. Thank you for joining HUTCHMED 2024 Full Year Results Call.
Read More
HUTCHMED (HCM) Upgraded to Buy: Here's Why
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
HUTCHMED (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
HUTCHMED to Announce 2024 Final Results
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).
Read More
About HUTCHMED (China) Limited (HCM)
- IPO Date 2016-03-16
- Website https://www.hutch-med.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Dr. Wei-Guo Su B.Sc., Ph.D.
- Employees 1811